1、癌症治疗疫苗ELI-002的人体临床试验结果 在这个一期临床试验里,研究人员使用的是固定剂量的ELI-002,疫苗设计则是针对KRAS基因G12D和KRAS基因G12R突变。总体上以增强淋巴结递送和免疫反应。 癌症疫苗ELI-002的设计 上面的图示是癌症...
这款突变既往一直被视为“无法成药”的靶点,然而ELI-002疫苗的成功研发,为这一难题提供了新的解决方案,该疫苗无需单独单独设计,即可刺激机体免疫系统识别和攻击癌细胞,免去了复杂的流程,节约了制作疫苗的耗时,具有广阔的应用前景,为病情...
[5]https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/an-exploratory-study-to-assess-the-safety-immunogenicity-and-preliminary-anti-tumor-activity-of-the-ebv-mrna-vaccine-wgc-043-injection-in-patie [6]https://www.esmo.org/oncology-news/proof-of-concept-for-the-safety-and-immuno...
KRAS突变是一种常见的基因突变类型,存在于多款癌种(如胰腺癌、肺癌、结直肠癌、肝癌、甲状腺癌、膀胱癌、卵巢癌、乳腺癌等)中。这款突变既往一直被视为“无法成药”的靶点,然而ELI-002疫苗的成功研发,为这一难题提供了新的解决方案,该疫苗 无需单独单独设计 ,即可 刺激机体免疫系统识别和攻击癌细胞,免去了复杂...
ELI-002 is an investigational AMP cancer vaccine that targets cancers driven by mutations in the KRAS gene. The vaccine combines 2 components: AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant, which can be administered subcutaneously.1 The 2-...
2019年,Darrell Irvine 作为通讯作者在SCIENCE发表题为“Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor”的文章。文章中,研究团队设计出了一种两亲性 CAR-T 配体(amph-ligands)疫苗,此类配体会促进 CAR-T 活化、大规模扩增,并增加抗肿瘤杀伤作用。在小鼠...
ELI-002 is an off-the-shelf vaccine targeting common KRAS tumor mutations demonstrating several key advantages: lymph node-targeted vaccine design, high immunogenicity, with balanced CD4+ and CD8+ T cell responses, HLA-agnostic activity, and targeting of vaccine antigens critical for tumor survival...
with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. ELI-002 is being studied in an ongoing, random...
(AMPLIFY-201)study of ELI-002 2P inNature Medicine. The paper, “Lymph Node Targeted, mKRAS-specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The phase 1 AMPLIFY-201 Trial”, details expanded and updated res...
Craig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.